Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary mediastinal large B-cell lymphoma.

Kerry J Savage1

  • 1British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada. ksavage@bccancer.bc.ca

The Oncologist
|May 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Blood advances·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers.

Cancer discovery·2026
Same author

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.

Haematologica·2026
Same journal

Target trial emulation studies in oncology: a comprehensive analysis.

The oncologist·2026
Same journal

Durable Response to Sotorasib in KRAS G12C-Mutant Intrahepatic Cholangiocarcinoma: A Case Report.

The oncologist·2026
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
See all related articles

Primary mediastinal large B-cell lymphoma (PMBCL) may have a better prognosis than diffuse large B-cell lymphoma. Further clinical trials are needed to confirm the effectiveness of intensified chemotherapy regimens and consolidative radiotherapy for PMBCL.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct lymphoma subtype.
  • PMBCL shares molecular features with nodular sclerosis classical Hodgkin's lymphoma.
  • Emerging data suggest a potentially more favorable outcome for PMBCL compared to diffuse large B-cell lymphoma (DLBCL).

Purpose of the Study:

  • To evaluate the efficacy of dose-dense and dose-intensive chemotherapy regimens for PMBCL.
  • To investigate the impact of rituximab on treatment outcomes in PMBCL.
  • To determine the benefit of consolidative radiotherapy in PMBCL management.

Main Methods:

  • Historical comparisons of treatment outcomes.
  • Analysis of molecular gene-expression signatures.

Related Experiment Videos

  • Review of clinical trial data (implied).

    • Main Results:

    • Dose-dense/intensive regimens may offer advantages over standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy.
    • The specific impact of rituximab addition and consolidative radiotherapy on PMBCL outcomes remains undetermined.

    Conclusions:

    • PMBCL may have a distinct and potentially more favorable prognosis than DLBCL.
    • Further clinical trials are essential to optimize treatment strategies for PMBCL, including the role of rituximab and radiotherapy.